Through their capacity to confer an increase in the proportion of integration events that are productive, together with improvements in the level of transgene expression, RNP CpG island vectors have many other potential applications, including use in mammalian cell-based in vitro screens for drug discovery, transgenic animals for basic research and drug discovery, and gene therapy.
Due to the large volume of protein sequences generated in the post-genomic era, it is extraordinarily important in both basic research and drug discovery to rapidly identify the attributes of a new protein's palmitoylation sites.
The National Institutes of Health (NIH) plays a vital role in basic research and early discovery, and we support sufficient federal funding for their work.
Proteins with multiple locations or dynamic feature of this kind are particularly interesting because they may have some very special biological functions intriguing to investigators in both basic research and drug discovery [2], [21].
It is, therefore, imperative for both basic research and drug discovery to understand the molecular mechanism of PI3Kγ signaling and its functional role in the immune system.
Therefore, a method to detect and quantify protein interactions with small molecules in a high-throughput format will have high impact on both basic research and drug discovery.
In particular, induced pluripotent stem cell lines derived from AD patients could be especially valuable for both basic research and drug discovery screening programs; several familial AD lines are currently in development.
We report here the industrialization of membrane protein microarrays suitable for basic research and drug discovery applications in numerous aspects of membrane biology, from multivalent ligand/receptor interactions to live cell assays.
Kishor Wasan (Cofounder/Director, Neglected Global Diseases Initiative and Professor, Faculty of Pharmaceutical Sciences, University of British Columbia) spoke about working as an academic scientist at the nexus of basic research and drug discovery and the challenges faced in founding the Neglected Global Diseases Initiative at the University of British Columbia (UBC).
